Recombinant Mouse Interferon Beta 1, Fibroblast

• Cat.No.: Ifnb1-37M
• Product Overview: Recombinant Mouse Interferon beta produced inE.Coliis a single, non-glycosylated polypeptide chain containing 162 amino acids and having a molecular mass of 19.8 kDa. Mouse IFN beta is purified by proprietary chromatographic techniques.

Specification

• Cat. No.: Ifnb1-37M
• Description: Interferon-beta 1b has antiviral, antibacterial and anticancer activities. Influenza A viruses not only inhibit IFN-beta gene induction but also supress Type-I IFN signaling via mechanism involving induction of the SOCS-3 protein. Intracellular bacteria and cytosolic poly (dA-dT) trigger IFN-beta responses in different human cells without requiring human ZBP1.
• Source: Escherichia Coli.
• Amino Acid Sequence: MINYKQLQLQERTNIRKCQELLEQL NGKINLTYRADFKIPMEMTEKMQKS YTAFAIQEMLQN VFLVFRNNFSS TGWNETIVVRLLDELHQQTVFLKTV LE EKQEERLT WEMSSTAL HLKSYYWRVQRYLKLMKYNSYAWMV VRAEIFR NFLIIRRLTRNFQN.
• Purity: Greater than 90.0% as determined by: (a) Analysis by RP-HPLC. (b) Analysis by SDS-PAGE.
• Formulation: IFN-b Mouse solution containing 10mM sodium phosphate pH-7.5 and 0.5M ammonium sulfate.
• Biological Activity: Determined in a viral cytopathic effect inhibition assay.
• Stability: Store the IFN-beta at 4°C for 4 weeks. Do not freeze/thaw.
• Tag: Non

Gene Information

• Gene Name: Ifnb1 interferon beta 1, fibroblast [ Mus musculus ]
• Synonyms: Ifnb1; interferon beta 1, fibroblast; Ifb; IFNB; IFN-beta; OTTMUSP00000008111; IFB; IFF; IFN-beta; MGC96956; OTTHUMP00000021131; Fibroblast interferon; interferon beta
• Gene ID: 15977
• mRNA Refseq: NM_010510
• Protein Refseq: NP_034640
• UniProt ID: P01575
• Chromosome Location: 4 42.6 cM
• Pathway: Cytokine-cytokine receptor interaction; Jak-STAT signaling pathway; Natural killer cell mediated cytotoxicity; Toll-like receptor signaling pathway
• Function: cytokine activity; cytokine receptor binding

Reviews

06/24/2021

The manufacturer not only ensures the provision of superior protein but also aids researchers with their solid technical support, offering the necessary resources to optimize experimental protocols.

08/29/2020

the IFNB1 protein offers numerous advantages for researchers conducting trials due to its high quality and stability.

11/08/2018

manufacturers or suppliers of proteins can play a crucial role in supporting researchers during trials.

Q&As

Are there any contraindications for IFNB1 treatment?

IFNB1 is generally not recommended for individuals with a history of hypersensitivity to interferons or other components of the drug. It should be used with caution in patients with certain pre-existing medical conditions.

Can IFNB1 be used in cancer treatment?

IFNB1 is being investigated for its potential role in cancer treatment due to its immunomodulatory effects. Clinical trials are ongoing to evaluate its efficacy in various types of cancer.

What are the potential side effects of IFNB1 treatment?

Common side effects include flu-like symptoms, injection site reactions, and changes in blood cell counts. Serious side effects are rare but can include liver problems and allergic reactions.

How is IFNB1 administered in clinical settings?

IFNB1 is often administered through subcutaneous or intramuscular injections. The frequency and dosage depend on the specific condition being treated.

In what other conditions is IFNB1 protein clinically utilized?

IFNB1 is also used in the treatment of certain viral infections, such as hepatitis B and C. It has antiviral properties that can inhibit viral replication.